A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.

AX, Zhu; RS, Finn; M, Mulcahy; J, Gurtler; W, Sun; JD, Schwartz; RP, Dalal; A, Joshi; RR, Hozak; Y, Xu; M, Ancukiewicz; RK, Jain; FW, Nugent; DG, Duda; K, Stuart

doi:10.1158/1078-0432.ccr-13-1442

Public

A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.

Shared by NobleBlocks on Oct 2, 2013 • 12:00 AM UTC

Authors:

Zhu AX

Finn RS

Mulcahy M

Abstract

Purpose To assess the efficacy and safety of the anti-VEGF receptor-2 (VEGFR-2) antibody ramucirumab as first-line therapy in patients with advanced hepatocellular carcinoma and explore potential circulating biomarkers.Experimental design Adults with advanced hepatocellular carcinoma and no prior sy...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!